JP2016515530A - 免疫調節薬および抗がん剤としてのトリプトリドの静脈内乳剤 - Google Patents

免疫調節薬および抗がん剤としてのトリプトリドの静脈内乳剤 Download PDF

Info

Publication number
JP2016515530A
JP2016515530A JP2016503315A JP2016503315A JP2016515530A JP 2016515530 A JP2016515530 A JP 2016515530A JP 2016503315 A JP2016503315 A JP 2016503315A JP 2016503315 A JP2016503315 A JP 2016503315A JP 2016515530 A JP2016515530 A JP 2016515530A
Authority
JP
Japan
Prior art keywords
triptolide
composition
sodium
oil
emulsion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016503315A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016515530A5 (https=
Inventor
ジェンファ アン，
ジェンファ アン，
ウェイグオ ハー，
ウェイグオ ハー，
ジョン エム． フィドラー，
ジョン エム． フィドラー，
ジョン エイチ． ムッサー，
ジョン エイチ． ムッサー，
Original Assignee
ファーマジェネシス， インコーポレイテッド
ファーマジェネシス， インコーポレイテッド
マイロレックス， エルエルシー
マイロレックス， エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ファーマジェネシス， インコーポレイテッド, ファーマジェネシス， インコーポレイテッド, マイロレックス， エルエルシー, マイロレックス， エルエルシー filed Critical ファーマジェネシス， インコーポレイテッド
Publication of JP2016515530A publication Critical patent/JP2016515530A/ja
Publication of JP2016515530A5 publication Critical patent/JP2016515530A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2016503315A 2013-03-15 2014-03-15 免疫調節薬および抗がん剤としてのトリプトリドの静脈内乳剤 Pending JP2016515530A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361794926P 2013-03-15 2013-03-15
US61/794,926 2013-03-15
PCT/US2014/030041 WO2014145303A1 (en) 2013-03-15 2014-03-15 Intravenous emulsions of triptolide as immunomodulators and anticancer agents i

Publications (2)

Publication Number Publication Date
JP2016515530A true JP2016515530A (ja) 2016-05-30
JP2016515530A5 JP2016515530A5 (https=) 2017-04-13

Family

ID=51537944

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016503315A Pending JP2016515530A (ja) 2013-03-15 2014-03-15 免疫調節薬および抗がん剤としてのトリプトリドの静脈内乳剤

Country Status (7)

Country Link
US (1) US20160038454A1 (https=)
EP (1) EP2968140A4 (https=)
JP (1) JP2016515530A (https=)
CN (1) CN105263475A (https=)
HK (1) HK1219228A1 (https=)
TW (1) TWI597071B (https=)
WO (1) WO2014145303A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021515048A (ja) * 2018-03-07 2021-06-17 シアン チェン アンドリュー 不溶性薬物用の水性製剤

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180061226A (ko) 2015-09-11 2018-06-07 와이즈에이씨가부시키가이샤 항cd26 항체와 다른 항암제를 조합한 암 치료용 조성물
US10342797B2 (en) 2016-03-13 2019-07-09 LivePet, LLC Solubility of therapeutic agents
CN107663225A (zh) * 2016-07-29 2018-02-06 欣凯医药化工中间体（上海）有限公司 一种氟代雷公藤内酯醇内酯环衍生物
CN108530511B (zh) * 2017-03-02 2021-06-22 欣凯医药化工中间体（上海）有限公司 一种c19-酰基化雷公藤甲素衍生物
CN106946975B (zh) * 2017-03-16 2020-08-14 上海天氏利医药科技有限公司 一种雷公藤甲素衍生物及其制备方法与制剂
CN106994129A (zh) * 2017-05-15 2017-08-01 王晓辉 雷公藤甲素及其衍生物在制备治疗和/或预防肺损伤疾病的药物中的应用
WO2018222351A1 (en) * 2017-05-27 2018-12-06 Pharmagenesis, Inc. Triptolide lactone derivatives as immunomodulators and anticancer agents
CN109771430A (zh) * 2019-03-15 2019-05-21 大连大学 甘氨胆酸在制备抗肿瘤药物中的应用
CN111494319A (zh) * 2020-06-15 2020-08-07 沈阳药科大学 雷公藤甲素复方组合物及其制备方法与应用
CN115466269A (zh) * 2021-06-11 2022-12-13 复旦大学 一种胆碱碳酸酯类前药及其制备方法和应用
CN114569554A (zh) * 2022-03-01 2022-06-03 福建省医学科学研究院 一种肿瘤靶向性雷公藤内酯醇乳液及其制备方法
CN114831962A (zh) * 2022-04-29 2022-08-02 福建省医学科学研究院 一种雷公藤内酯醇固体脂质纳米粒及其滴丸的制备方法
CN117088935A (zh) * 2022-05-20 2023-11-21 上海维洱生物医药科技有限公司 一种雷公藤甲素木蜡酸酯及其脂质体与制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007526331A (ja) * 2004-03-02 2007-09-13 ファーマジェネシス， インコーポレイテッド 免疫調節剤および抗癌剤としてのトリプトライドラクトン環誘導体
JP2009506120A (ja) * 2005-08-29 2009-02-12 セプシキュア、リミテッド、ライアビリティ、カンパニー グラム陽性菌によって引き起こされる状態の治療又は予防方法
CN102552137A (zh) * 2012-02-22 2012-07-11 福建医科大学 雷公藤内酯醇脂肪乳注射剂及其制备方法
CN102793674A (zh) * 2011-05-26 2012-11-28 澳门科技大学 一种雷公藤甲素固体脂质纳米颗粒及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3631795A (en) * 1994-09-15 1996-03-29 Pharmagenesis, Inc. Composition and method for immunotherapy
WO2004058246A1 (en) * 2002-12-17 2004-07-15 Pharmagenesis, Inc. Triptolide derivatives as immunomodulator and anticancer agents
CN101485629B (zh) * 2008-01-16 2013-01-23 沈阳药科大学 一种给药系统及其制备方法
TW201138782A (en) * 2010-04-26 2011-11-16 Besins Healthcare Lu Sarl Low-oil pharmaceutical emulsion compositions comprising progestogen

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007526331A (ja) * 2004-03-02 2007-09-13 ファーマジェネシス， インコーポレイテッド 免疫調節剤および抗癌剤としてのトリプトライドラクトン環誘導体
JP2009506120A (ja) * 2005-08-29 2009-02-12 セプシキュア、リミテッド、ライアビリティ、カンパニー グラム陽性菌によって引き起こされる状態の治療又は予防方法
CN102793674A (zh) * 2011-05-26 2012-11-28 澳门科技大学 一种雷公藤甲素固体脂质纳米颗粒及其制备方法和应用
CN102552137A (zh) * 2012-02-22 2012-07-11 福建医科大学 雷公藤内酯醇脂肪乳注射剂及其制备方法

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021515048A (ja) * 2018-03-07 2021-06-17 シアン チェン アンドリュー 不溶性薬物用の水性製剤
JP7561629B2 (ja) 2018-03-07 2024-10-04 シアン チェン アンドリュー 不溶性薬物用の水性製剤

Also Published As

Publication number Publication date
EP2968140A4 (en) 2016-11-16
US20160038454A1 (en) 2016-02-11
TW201440812A (zh) 2014-11-01
WO2014145303A1 (en) 2014-09-18
HK1219228A1 (zh) 2017-03-31
TWI597071B (zh) 2017-09-01
CN105263475A (zh) 2016-01-20
EP2968140A1 (en) 2016-01-20

Similar Documents

Publication Publication Date Title
JP2016515530A (ja) 免疫調節薬および抗がん剤としてのトリプトリドの静脈内乳剤
US5843452A (en) Immunotherapy composition and method
JP5057966B2 (ja) 免疫調節剤および抗癌剤としてのトリプトライドラクトン環誘導体
JP6803898B2 (ja) オメガ−３脂肪酸およびトマトリコペンを含む抗炎症性相乗的組み合わせ
JP2017535608A (ja) 癌標的化薬物ビヒクルとしてのリン脂質エーテル類似体
US8048860B2 (en) Butanol extract of Bidens pilosa
JP4680589B2 (ja) アポトーシスおよび免疫抑制の調節のためのトリプトリド誘導体
JP2011525486A (ja) 活動亢進性免疫系を治療するためのシクロリグナンの使用
US20230129151A1 (en) Compositions and methods for the treatment of myelin related and inflammation related diseases or disorders
JP2006513209A (ja) 免疫調節因子および抗癌剤としてのトリプトライド誘導体
US5759550A (en) Method for suppressing xenograft rejection
JP6062065B2 (ja) 過敏性腸症候群を治療するためのアルピニア種抽出物
JP2023517736A (ja) 免疫調節剤
CN114555583B (zh) 化合物及其在治疗自身免疫性疾病中的用途
WO2004026298A1 (en) Derivatives of triptolide having high immunosuppressive effect and high water solubility, and uses thereof
WO2017209270A1 (ja) ２５－ヒドロキシコレステロール又はその類縁体コレステロールを有効成分として含有してなる、活性化されたｔ細胞及び／又はｂ細胞に選択的な細胞死誘導剤又は細胞死促進剤
WO1995013082A1 (en) Immunotherapy composition and method
WO2019032640A1 (en) MEK / P13K, JAK / MEK, JAK / P13K / MTOR AND MEK / P13K / MTOR BIKE INHIBITORS AND METHODS FOR ENHANCING LYMPHATIC ABSORPTION, BIOAVAILABILITY AND SOLUBILITY OF THERAPEUTIC COMPOUNDS
JP2013503908A (ja) ニューロキニン２受容体活性に関連する障害または疾患を治療するための化合物
EP2393818A2 (en) Triptolide c-ring derivatives as anticancer agents and immune modulators
KR100674222B1 (ko) 세라시아 마르세센스 ｂ-1231 ｋｃｔｃ 0386ｂｐ로부터분리한 프로디지오신을 유효성분으로 포함한 급성이식편대숙주병의 예방 및 치료용 조성물
KR20250027605A (ko) 자가면역질환 또는 암의 치료 또는 예방용 약학 조성물
TWI423809B (zh) 抑制乙醯膽鹼受器經活化而導致癌細胞增生的醫藥組合物
CN103896812A (zh) N，n’－二环己基－n－高级脂肪酸酰脲类似物及其制药用途
JP2021088545A (ja) 環状ペプチド化合物、キヌレニン産生阻害剤及び医薬組成物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170309

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170309

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180301

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20180301

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180717